Advanced Search
Current and Breaking News for Professionals, Consumers and Media




Children's Health Author: Staff Editor Last Updated: Sep 7, 2017 - 10:10:41 PM



Teva’s Needle-Free Tjet® Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment

By Staff Editor
Feb 7, 2010 - 7:00:36 AM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page
Free Supplies and Enhanced Support Programs Keep Parents’ Needs In Mind

(HealthNewsDigest.com) - Jerusalem, Israel, – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced the availability of new resources to support the recently introduced Tjet® injector system, a needle-free device designed to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal endogenous growth hormone. The Tjet® device uses a needle-free delivery system that releases the same amount of TEV-TROPIN® as a traditional syringe in two seconds.

To help families with a growth hormone deficiency (GHD) diagnosis, Teva has launched an updated web site (http://tevtropin.com/) that includes information specifically tailored for kids, teens and parents, and caregivers; instructional videos to help families learn about the Tjet® device; and information about Growth Solutions®, the company’s comprehensive patient support program that offers training and education, as well as insurance and reimbursement assistance.

“The Tjet® device is a great option for children with growth hormone deficiency, especially those who dislike needles,” states Paul Saenger, M.D. “The families in my practice have found that the Tjet® is a kid-friendly way to administer the daily medication that their children need to help reach their normal heights.”

As part of its commitment to pediatric patient care, Teva will also provide the Tjet® device and replacement supplies free of charge with all prescriptions for TEV-TROPIN® when requested by a physician.

The Tjet® device works by releasing a thin stream of TEV-TROPIN® that penetrates the stratum corneum (outermost layer skin) and is delivered into the subcutaneous (below the skin) tissue in two seconds through a tiny opening in the skin less than one third the size of a 30-gauge needle. With flexible dosing in increments of 0.05 mg, the Tjet® device delivers the prescribed dose of TEV-TROPIN® with one click of a button. The Tjet® device can be used on the back of the upper arm, the upper outer thigh, stomach, or buttocks. The Tjet® device has an eco-friendly design that means less waste compared to needle-pen devices or traditional syringe administration.

For more information about GHD and the Tjet® device, visit TEV-TROPIN

About Growth Hormone Deficiency

GHD affects an estimated 22,000 children in the United States. GHD is a disorder where the body produces an insufficient amount of growth hormone or none at all. Without enough growth hormone, a child may not be able to grow at an expected rate or reach his or her anticipated adult height.

About TEV-TROPIN®

TEV-TROPIN® is indicated only for the treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone (GH).

Important Safety Information for TEV-TROPIN®

Growth hormone may be used in children with confirmed Prader-Willi Syndrome only when diagnosed with GHD. Children who are severely overweight, have breathing problems while awake or asleep, and have lung infections should stop use of growth hormone and consult a physician. This may occur more in boys.

Changes in eyesight, headaches, nausea, and vomiting may occur. Frequent eye examinations should be done before and during treatment. Patients should be observed for elevated blood glucose, underactive thyroid, underactive pituitary, skin cancers, development of a limp, or complaint of hip or knee pain. Patients with rapid onset critical illness as a result of open heart or abdominal surgery, multiple accidental trauma, or rapid onset respiratory failure should not be started on TEV-TROPIN®. Patients with injury or active cancer in the brain, eye problems related to diabetes, or bones that have stopped growing should not receive recombinant growth hormone.

When TEV-TROPIN® is administered at the same site over a long period of time, damage to the tissue may result. This can be avoided by rotating the injection site.

Because TEV-TROPIN® increases growth rate, patients with a history of curvature of the spine (scoliosis) should be monitored.

TEV-TROPIN® may interfere with other drugs removed from the body by the liver and careful monitoring is advisable.

The liquid provided to mix TEV-TROPIN® should not be used in newborns because of associated toxicity. Doses of reconstituted TEV-TROPIN® greater than 1 mL are not recommended. Consult your child's physician for doses greater than 1 mL. Do not exceed the dose recommended by your child's physician.

In studies of GHD children, headaches occurred infrequently. Injection-site reactions, for instance pain or bruising, occurred in 8 of the 164 treated patients.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80% of Teva's sales are in North America and Europe.

Please click here for full prescribing information.

TEV-TROPIN® and Tjet® are registered trademarks of Teva Pharmaceuticals USA.

Growth Solutions® is a registered service mark of Teva Pharmaceuticals USA.

Subscribe to our FREE Ezine and be eligible for Health News, discounted products/services and coupons related to your Health. We publish 24/7.
HealthNewsDigest.com
We videotape Press Conferences, produce Satellite MediaTour's, B-rolls, PSA's, - all with distribution: HealthyTelevisionProductions[email protected]







Top of Page

HealthNewsDigest.com

Children's Health
Latest Headlines


+ Helping Children Cope with School Shooting
+ Deaf Children with Learning Delays Benefit From Cochlear Implants
+ Provide Antibody Testing to Help Study Long COVID in Children 
+ New Resources for Clean and Healthy Child Care
+ Do Early Therapies Aid Very Young Children With or at High Likelihood for Autism?
+ Diet Has Key Role in ADHD Symptoms in Children
+ Home Environment Protects Against Development of Heart Disease Risk Factors After Child Abuse
+ Children in Underserved Communities Are at Increased Risk of Being Admitted to the Pediatric ICU and of Dying There
+ Children’s Physical Activity Levels Fell Below National Guidelines in Wake of Pandemic
+ Potential Pathway Linking Infant Infections to Cardiovascular Disease



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions